Transparency Rising
Events
Transparency Rising 2026
A Forum for Market Innovators
When: Monday, May 18 – Wednesday, May 20, 2026
Where: Nopsi Hotel, New Orleans
The Prescription Drug Marketplace Is Undergoing a Fundamental Economic Realignment.
Join the Conversation.
National reforms are bringing rebate flows, affiliate economics, and pricing structures into clearer view — creating a more disciplined, transparent operating environment across the pharmacy supply chain. Clear data and aligned incentives are increasingly replacing opaque arrangements, empowering patients, and plan sponsors to make informed, value-driven decisions.
Transparency Rising 2026 convenes the leaders designing this next-generation market framework.
Hosted by the nation’s largest coalition of transparent PBMs — and the only platform singularly dedicated to institutionalizing this model — the forum brings together:
• Transparent PBMs and aligned market operators
• Leading biopharmaceutical research companies and biosimilar innovators
• Employers and public plan sponsors
• Investors and capital partners
• Policymakers and regulatory leaders
Adoption of transparent PBMs has more than doubled — rising from 12% to 31% in a single year. A 19-point market share shift reflects a decisive change in how employers purchase pharmacy benefit services.
Transparency Rising sits at the intersection of policy, capital, and scientific innovation — where clearer economics translate into measurable affordability and sustainable market growth.
We look forward to welcoming industry leaders and partners to New Orleans.
Monday, May 18 – Wednesday, May 20, 2026
NOPSI Hotel | New Orleans
2026 Key Topics & Strategic Themes
National PBM Reform: From Legislation to Market Execution
How recent federal reforms are reshaping rebate flows, affiliate economics, fiduciary alignment, and contracting standards — and what implementation means for employers, manufacturers, and capital markets.
Labor and Public Plans as Change Agents
The growing role of unions, Taft-Hartley plans, and public purchasers in accelerating transparent benefit models — and how collective purchasing power is influencing national market standards.
Advancing Choice Through Aligned Brokers and Consultants
The evolution of broker and consultant incentives in a post-opacity environment. Building competitive pathways that prioritize plan sponsor alignment, transparent compensation structures, and disciplined governance.
FTC, Regulatory Oversight & Antitrust Enforcement
How enforcement priorities are influencing vertical integration, rebate aggregation, market concentration, and competitive access — and what operators should anticipate in a more active regulatory landscape.
Media Perspectives in a Shifting Market
National reporters and industry analysts on how coverage of PBM economics, rebate flows, and drug pricing transparency is shaping public perception and policy momentum.
GLP-1s, High-Cost Therapies & “Food Is Medicine”
Managing next-generation spend categories — from GLP therapies to value-based nutrition and preventive health strategies — within transparent, net-cost aligned frameworks.
AI and the Next Era of Drug Benefit Intelligence
How artificial intelligence is transforming formulary design, risk stratification, rebate analysis, fraud detection, and data transparency — and what governance standards must evolve alongside it.
Direct-to-Employer (DTE) & Direct-to-Consumer (DTC) Innovation
New distribution models, transparent pharmacy platforms, digital health ecosystems, and employer contracting strategies that are redefining how therapies reach patients.
A look back at
Transparency Rising 2025
- Tariffs, Group-Purchasing and Transparency in the Global Supply Chains
- Pass-thru PBMs as a prescription to waste, fraud, and abuse and employer risk
- Transparent clinical approaches prioritizing patients and savings
- Congressional, legal, regulatory action empowering transparency
- How pass-thru markets work: Employers perspectives
It’s time to take action.
Transparency is important to any industry, but in health care, the lives of patients truly depend on it. Failing to uphold this value through openness and clarity leads to high drug prices and prevents American businesses from growing and competing.
As a prescription, powerful platforms and business solutions have emerged, anchored by thousands of proven American companies and partnerships, clearly demonstrating the market is ready and rising to adopt transparency.
Our goal is clear: Safeguard main street and employers, improve patient outcomes, and produce the lowest-net-cost and pass-through marketplaces, for drug pricing and healthcare.